Key points
- The label indicates Adderall XR for ADHD in adults and pediatric patients 6 years and older.
- Each capsule holds immediate-release and delayed-release beads; blood levels peak about 7 hours after a dose, about 4 hours later than the immediate-release tablet.
- The most common adult side effects on the label include dry mouth, loss of appetite, insomnia, headache, weight loss, nausea, anxiety and a fast heart rate.
- It is contraindicated with MAOIs or within 14 days of stopping one, and alkalinizing agents such as some antacids raise its levels.
- Schedule II prescriptions cannot be refilled under federal rules, and New Jersey adds in-person visit requirements for adults who start by telehealth.
Adderall XR is the extended-release version of mixed amphetamine salts. Unlike the immediate-release tablet, its FDA label names adults directly. This page walks through the label as of October 2026: what the medication is, how its capsule works, what the adult study showed, the warnings, and the New York and New Jersey rules that apply. It is general information. Decisions about any medication belong to you and your prescriber.
What it is
Adderall XR capsules contain equal amounts of four salts: dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate and amphetamine aspartate monohydrate, the same ingredients as immediate-release Adderall. It is a central nervous system (CNS) stimulant in the amphetamine family, and amphetamine is a Schedule II controlled substance under federal law.
How the capsule works
The label explains that each capsule holds two kinds of beads, immediate-release and delayed-release, which "prolong the release of amphetamine compared to the ADDERALL (immediate-release) tablet." In the label's pharmacokinetic data, blood levels peaked about 7 hours after a dose of Adderall XR, roughly 4 hours later than with the immediate-release tablet. That is why it is classed as long-acting and taken once a day, on waking. The label warns that afternoon doses should be avoided because of the potential for insomnia. For how bead systems compare with other release technologies, see extended-release ADHD medications explained.
According to the label, the capsule can be swallowed whole, or opened and the entire contents sprinkled on applesauce, eaten right away without chewing the beads. A single capsule's contents should not be divided. It can be taken with or without food.
Is it approved for adults?
Yes. The label says Adderall XR "is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older." A 2025 label update added a limitation: it is not recommended for children under 6, who had higher drug exposure and more side effects such as weight loss.
The adult approval rests on a four-week, double-blind, placebo-controlled study of 255 adults who met DSM-IV criteria for ADHD. All of the Adderall XR groups improved more than placebo on the ADHD Rating Scale. The label notes that Adderall XR "has not been studied in the geriatric population," so evidence in older adults is limited.
More broadly, a 2018 network meta-analysis in Lancet Psychiatry found that amphetamines reduced clinician-rated core ADHD symptoms in adults more than placebo, and its authors concluded the evidence "supports ... amphetamines in adults" as a first choice for short-term treatment. The same analysis found amphetamines less well tolerated than placebo in adults. These were short-term trials. Does ADHD treatment work in adults? explains what the numbers mean.
The boxed warning
Adderall XR carries the stimulant class boxed warning the FDA required on May 11, 2023: "ABUSE, MISUSE, and ADDICTION." The label says it "has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction," and that misuse can result in overdose and death. Prescribers are asked to assess each person's risk before prescribing and to keep reassessing. See ADHD medication misuse and addiction risk.
Common side effects in adults
The label lists the most common adverse reactions in adults (at least 5% and more often than with placebo) as:
- dry mouth, loss of appetite and weight loss
- insomnia and headache
- nausea and diarrhea
- anxiety, agitation and dizziness
- a fast heart rate (tachycardia)
- weakness (asthenia) and urinary tract infections
Serious warnings in the label include risks for people with serious heart disease, increases in blood pressure and heart rate, psychiatric effects (worsening psychosis, manic episodes, rare new psychotic or manic symptoms), seizures, Raynaud's phenomenon and other circulation problems in fingers and toes, serotonin syndrome, and new or worsening tics. ADHD medication, heart health and blood pressure and side effects in adults cover these in more depth.
Who should not take it
The label's contraindications are:
- Known hypersensitivity to amphetamine or other components of the capsule.
- Taking an MAOI, or within 14 days of stopping one (including linezolid or intravenous methylene blue), because of the risk of hypertensive crisis.
The label also lowers the recommended amount for people with severe kidney impairment and does not recommend Adderall XR for end-stage renal disease.
Interactions to mention
- MAOIs: contraindicated.
- Serotonergic drugs (for example SSRIs, SNRIs, triptans, tricyclic antidepressants) and CYP2D6 inhibitors: higher risk of serotonin syndrome.
- Alkalinizing agents such as some antacids raise amphetamine levels and should be avoided with it; acidifying agents lower levels.
- Proton pump inhibitors: amphetamine peaks sooner.
- Tricyclic antidepressants: can increase cardiovascular effects.
- Brain imaging: the label says Adderall XR can interfere with a DaTscan (ioflupane I-123) and cause false-positive results, so tell the imaging team you take it.
More detail is in ADHD medication drug interactions.
Pregnancy and breastfeeding
The label says published epidemiologic studies and postmarketing reports "have not identified a drug-associated risk of major birth defects and miscarriage," while premature delivery and low birth weight have been seen in infants of mothers taking amphetamines. A National Pregnancy Registry for Psychostimulants collects outcome data. On breastfeeding, the label says amphetamine is present in human milk and advises that breastfeeding is not recommended during treatment. The NIH LactMed entry adds that some experts consider prescribed doses compatible with nursing if the infant is monitored. Plan this with your prescriber; see ADHD in pregnancy and postpartum.
Generics, cost and supply
Generic mixed amphetamine salts extended-release capsules are sold by several manufacturers and are listed on DailyMed. Prices depend on your plan and pharmacy, so ask them directly; the New York cost guide and New Jersey cost guide explain the questions to ask. As of October 19, 2026, the FDA shortage database listed the immediate-release mixed amphetamine salts tablets as a current shortage; it did not list the extended-release capsules. Local stock still varies, so call ahead.
New York and New Jersey rules
Federal rules prohibit refills of Schedule II prescriptions, though a prescriber may issue multiple dated prescriptions covering up to a 90-day supply.
- New York: prescribers check the I-STOP registry before prescribing, and state supply and timing rules apply. See New York's rules for ADHD stimulant prescriptions and telehealth prescriptions in New York.
- New Jersey: P.L.2026, c.40 (effective July 8, 2026) requires adults located in New Jersey who start a Schedule II stimulant by telehealth to have an in-person visit within 30 days, a contact every three months, and an in-person visit at least yearly. Before any controlled substance is started, state rules require a history, an exam, an NJPMP check and a treatment plan. See New Jersey's rules.
- Federal telehealth: as of October 2026, the DEA telemedicine flexibilities for controlled substances run through December 31, 2026.
Dr. Shershow, licensed in New York and New Jersey, offers medication management when medication is appropriate, with follow-up by secure video. The office can explain how visits work for patients located in New Jersey.
Questions to ask your prescriber
- Does a once-daily capsule fit my work hours, or would I need something shorter or longer?
- What should I do if I have trouble sleeping?
- Is it all right to open the capsule if I have trouble swallowing?
- Which of my medications, antacids or supplements could interact?
- How will we monitor blood pressure, heart rate, mood and appetite?
To compare with similar choices, see Adderall IR vs XR, Adderall vs Vyvanse and the longer-acting Mydayis. Never start, stop or change a medication without your prescriber.
Questions
Is Adderall XR approved for adults?
Yes. The FDA label indicates it for ADHD in adults and pediatric patients 6 years and older. The adult approval is supported by a four-week placebo-controlled study in 255 adults.
Can I open an Adderall XR capsule?
The label allows swallowing the capsule whole or opening it and sprinkling all the contents on applesauce, eaten right away without chewing. Do not split a capsule's contents. Ask your prescriber or pharmacist before changing how you take it.
How long does Adderall XR last?
It is a long-acting, once-daily capsule. The label shows blood levels peaking about 7 hours after a dose and warns against afternoon doses because of insomnia. How long it helps varies from person to person.
Can antacids affect Adderall XR?
Yes. The label says alkalinizing agents, including some gastrointestinal antacids, raise amphetamine levels and should be avoided with it, while acidifying agents lower levels. Proton pump inhibitors make amphetamine peak sooner.
Is Adderall XR in shortage?
As of October 19, 2026, the FDA shortage database listed immediate-release mixed amphetamine salts tablets as a current shortage but did not list the extended-release capsules. Pharmacy stock can still vary.
Sources
- DailyMed: Adderall XR (mixed amphetamine salts) extended-release capsules, prescribing information (label updated April 30, 2026)
- Drugs@FDA: Adderall XR label, NDA 021303, revision dated April 2026 (PDF)
- DailyMed: generic mixed amphetamine salts extended-release capsules (Sun Pharmaceutical), prescribing information
- US Food and Drug Administration: FDA updating warnings to improve safe use of prescription stimulants (May 11, 2023)
- Cortese et al., Lancet Psychiatry 2018;5(9):727-738: network meta-analysis of ADHD medications in children, adolescents and adults
- openFDA drug shortages: mixed amphetamine salts tablets, status Current, first posted October 12, 2022 (checked October 19, 2026)
- NIH LactMed: Amphetamine (Drugs and Lactation Database)
- eCFR: 21 CFR 1306.12, Refilling prescriptions; issuance of multiple prescriptions
- NYS Department of Health: 10 NYCRR 80.63, Prescribing (I-STOP registry check)
- New Jersey Legislature: P.L.2026, c.40 (telehealth prescribing of Schedule II stimulants, effective July 8, 2026)
- New Jersey Administrative Code 13:35-7.6: Limitations on prescribing controlled dangerous substances
- Federal Register: Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications (December 31, 2025)
